Curated News
By: NewsRamp Editorial Staff
May 19, 2025
Republican Lawmakers Push for Psychedelic Therapy for Veterans
TLDR
- Rep. Luttrell leads Republican push for therapeutic psychedelics in veteran mental health, driving innovation in NRx Pharmaceuticals.
- Rep. Luttrell advocates for science-based, supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA for treating PTSD and depression.
- Rep. Luttrell's efforts aim to improve mental health treatment for veterans, promoting healing and resilience through innovative psychedelic therapies.
- NRx Pharmaceuticals and HOPE Therapeutics emerge as leaders in developing ketamine-based treatments for veteran mental health, signaling a shift in treatment approaches.
Impact - Why it Matters
This news highlights a significant shift in mental health treatment for veterans, with key lawmakers supporting the use of psychedelics. The involvement of NRx Pharmaceuticals in developing treatments underscores the growing importance of innovative solutions for mental health issues among veterans.
Summary
Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, along with Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), are leading a movement advocating for the therapeutic use of psychedelics to treat PTSD among veterans. Despite regulatory setbacks, they are pushing for science-based access to drugs like ibogaine, psilocybin, and MDMA. NRx Pharmaceuticals and its subsidiary HOPE Therapeutics are at the forefront of veteran-focused psychedelic innovation, developing ketamine-based treatments for mental health issues.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Republican Lawmakers Push for Psychedelic Therapy for Veterans
